SI2753352T2 - Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba - Google Patents

Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba

Info

Publication number: SI2753352T2
Authority: SI; Slovenia
Prior art keywords: toxin; difficile; proteins; isolated polypeptide; polypeptide
Prior art date: 2010-09-03

Application number

SI201131113T

Other languages

English (en)

Other versions

SI2753352T1 (sl

Inventor

Larry Ellingsworth

David Flyer

Jing-Hui Tian

Steven Fuhrmann

Stefanie Kluepfel-Stahl

Gregory Glenn

Kerstin Westritschnig

Original Assignee

Valneva Austria Gmbh

Valneva Usa, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-03

Filing date

2011-09-05

Publication date

2022-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2753352(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-05 Application filed by Valneva Austria Gmbh, Valneva Usa, Inc. filed Critical Valneva Austria Gmbh

2017-06-30 Publication of SI2753352T1 publication Critical patent/SI2753352T1/sl

2022-10-28 Publication of SI2753352T2 publication Critical patent/SI2753352T2/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SI201131113T 2010-09-03 2011-09-05 Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba SI2753352T2 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US37989210P	2010-09-03	2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en)	2010-09-03	2011-09-05	Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
EP11769799.5A EP2753352B2 (en)	2010-09-03	2011-09-05	Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (2)

Publication Number	Publication Date
SI2753352T1 SI2753352T1 (sl)	2017-06-30
SI2753352T2 true SI2753352T2 (sl)	2022-10-28

Family

ID=44799993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201131113T SI2753352T2 (sl)	2010-09-03	2011-09-05	Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba

Country Status (22)

Country	Link
US (7)	US9598472B2 (sl)
EP (3)	EP3167899B1 (sl)
JP (1)	JP6121421B2 (sl)
KR (1)	KR101907434B1 (sl)
CN (1)	CN103957931B (sl)
AU (1)	AU2011298306B2 (sl)
BR (1)	BR112014004896B1 (sl)
CA (1)	CA2873272C (sl)
CY (1)	CY1118664T1 (sl)
DK (1)	DK2753352T4 (sl)
ES (2)	ES2631032T5 (sl)
HR (1)	HRP20170193T4 (sl)
HU (1)	HUE033342T2 (sl)
LT (1)	LT2753352T (sl)
MX (1)	MX350126B (sl)
PL (1)	PL2753352T5 (sl)
PT (1)	PT2753352T (sl)
RS (1)	RS55707B2 (sl)
SI (1)	SI2753352T2 (sl)
SM (1)	SMT201700124T1 (sl)
WO (1)	WO2012028741A1 (sl)
ZA (1)	ZA201400610B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000061762A1 (en) *	1999-04-09	2000-10-19	Techlab, Inc.	RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
EP3167899B1 (en)	2010-09-03	2021-03-24	Valneva Austria GmbH	Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
MX391236B (es)	2011-04-22	2025-03-21	Wyeth Llc	Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
AU2016203241B2 (en) *	2011-05-27	2018-05-10	Glaxosmithkline Biologicals S.A.	Immunogenic composition
EP3564378B1 (en)	2011-05-27	2023-11-01	GlaxoSmithKline Biologicals SA	Immunogenic composition
SG11201402375VA (en)	2011-12-08	2014-10-30	Novartis Ag	Clostridium difficile toxin-based vaccine
AR089797A1 (es)	2012-01-27	2014-09-17	Merck Sharp & Dohme	Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US8986704B2 (en)	2012-07-06	2015-03-24	Valneva Austria Gmbh	Mutant fragments of OspA and methods and uses relating thereto
BR122016023101B1 (pt)	2012-10-21	2022-03-22	Pfizer Inc	Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
AU2013354186A1 (en) *	2012-12-05	2014-06-12	Glaxosmithkline Biologicals S.A.	Immunogenic composition
GB201223342D0 (en) *	2012-12-23	2013-02-06	Glaxosmithkline Biolog Sa	Immunogenic composition
GB2525177A (en) *	2014-04-14	2015-10-21	New Royal Holloway & Bedford	Vaccine
ES2870506T3 (es) *	2015-02-19	2021-10-27	Immune Biosolutions Inc	Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos
CA3014498A1 (en) *	2016-03-21	2017-09-28	Children's Medical Center Corporation	Compositions and methods for inhibiting wnt signaling
US12018054B2 (en)	2017-04-13	2024-06-25	Valneva Austria Gmbh	Multivalent OspA polypeptides and methods and uses relating thereto
EP3810163A1 (en)	2018-06-19	2021-04-28	GlaxoSmithKline Biologicals SA	Immunogenic composition
EP3931217A1 (en) *	2019-02-25	2022-01-05	PreviPharma Consulting GmbH	Epitopes of clostridium difficile toxins a and b and uses thereof
WO2021205022A1 (en)	2020-04-09	2021-10-14	Valneva Austria Gmbh	Improved methods of producing a lipidated protein
GB202205833D0 (en)	2022-04-21	2022-06-08	Glaxosmithkline Biologicals Sa	Bacteriophage
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine
WO2024160901A1 (en)	2023-02-02	2024-08-08	Glaxosmithkline Biologicals Sa	Immunogenic composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6018026A (en)	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en)	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5736139A (en)	1989-10-31	1998-04-07	Ochidian Pharmaceuticals, Inc.	Treatment of Clostridium difficile induced disease
US5547871A (en)	1993-01-25	1996-08-20	American Cyanamid Company	Heterologous signal sequences for secretion of insect controlling proteins
EP0772619B2 (en)	1994-07-15	2010-12-08	The University of Iowa Research Foundation	Immunomodulatory oligonucleotides
DE69535530D1 (de) *	1994-10-24	2007-08-16	Ophidian Pharm Inc	Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
ATE195878T1 (de)	1995-07-07	2000-09-15	Oravax Inc	Toxine und toxoide von clostridium difficile als schleimhautadjuvans
US5919463A (en) *	1995-07-07	1999-07-06	Oravax, Inc.	Clostridium difficle toxins as mucosal adjuvants
CA2267523A1 (en)	1996-10-04	1998-04-09	Auckland Uniservices Limited	Regulation of neural enzymes
EP0952850A2 (en)	1996-12-31	1999-11-03	Altea Technologies, Inc.	Microporation of tissue for delivery of bioactive agents
WO2000061762A1 (en)	1999-04-09	2000-10-19	Techlab, Inc.	RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
US6733760B1 (en)	1999-04-09	2004-05-11	Techlab, Inc.	Recombinant toxin A/toxin B vaccine against Clostridium difficile
AT408721B (de)	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de)	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de)	2000-06-08	2003-02-25	Cistem Biotechnologies Gmbh	Antigene zusammensetzung
RU2413520C2 (ru)	2000-06-08	2011-03-10	Интерселл Аг	Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
CA2418854A1 (en)	2000-08-17	2002-02-21	Jorg Fritz	A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
EP1390495B1 (en)	2001-05-21	2007-07-04	Intercell AG	Immunostimulatory oligodeoxynucleic molecules
WO2003047602A1 (en)	2001-12-07	2003-06-12	Intercell Ag	Immunostimulatory oligodeoxynucleotides
DK1766093T3 (da) *	2004-02-06	2011-10-03	Univ Massachusetts	Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
KR20070043043A (ko)	2004-08-23	2007-04-24	테바 파마슈티컬 인더스트리즈 리미티드	고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
WO2007146139A2 (en) *	2006-06-08	2007-12-21	Cornell Research Foundation, Inc.	Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
EP1921149A1 (en) *	2006-11-13	2008-05-14	AEterna Zentaris GmbH	Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
EP2167119B1 (en) *	2007-06-14	2016-08-24	The Secretary of State for Health	Chemically modified peptides with improved immunogenicity
WO2009035707A1 (en)	2007-09-14	2009-03-19	Acambis Inc.	Pharmaceutical compositions containing clostridium difficile toxoids a and b
CA2733425A1 (en) *	2008-08-06	2010-02-11	Emergent Product Development Uk Limited	Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) †	2009-11-16	2011-05-19	University Of Maryland Baltimore	Multivalent live vector vaccine against clostridium difficile-associated disease
GB0921288D0 (en)	2009-12-04	2010-01-20	Health Prot Agency	Therapies for preventing or suppressing clostridium difficile infection
JP5965389B2 (ja) *	2010-04-15	2016-08-03	プロゲニクスファーマシューティカルズインコーポレーテッドＰｒｏｇｅｎｉｃｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
EP3167899B1 (en)	2010-09-03	2021-03-24	Valneva Austria GmbH	Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
MX391236B (es) *	2011-04-22	2025-03-21	Wyeth Llc	Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
EP3564378B1 (en)	2011-05-27	2023-11-01	GlaxoSmithKline Biologicals SA	Immunogenic composition
GB201206070D0 (en) *	2012-04-04	2012-05-16	Health Prot Agency	Clostridium difficile antigens
AU2013354186A1 (en)	2012-12-05	2014-06-12	Glaxosmithkline Biologicals S.A.	Immunogenic composition
GB201223342D0 (en)	2012-12-23	2013-02-06	Glaxosmithkline Biolog Sa	Immunogenic composition
US9181632B1 (en) *	2013-09-09	2015-11-10	Merck Sharp & Dohme Corp.	C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

2011
- 2011-09-05 EP EP16204515.7A patent/EP3167899B1/en active Active
- 2011-09-05 HU HUE11769799A patent/HUE033342T2/en unknown
- 2011-09-05 RS RS20170202A patent/RS55707B2/sr unknown
- 2011-09-05 MX MX2014002595A patent/MX350126B/es active IP Right Grant
- 2011-09-05 SM SM20170124T patent/SMT201700124T1/it unknown
- 2011-09-05 JP JP2014527505A patent/JP6121421B2/ja active Active
- 2011-09-05 US US14/342,565 patent/US9598472B2/en active Active
- 2011-09-05 PT PT117697995T patent/PT2753352T/pt unknown
- 2011-09-05 KR KR1020147005813A patent/KR101907434B1/ko active Active
- 2011-09-05 CA CA2873272A patent/CA2873272C/en active Active
- 2011-09-05 BR BR112014004896-7A patent/BR112014004896B1/pt active IP Right Grant
- 2011-09-05 AU AU2011298306A patent/AU2011298306B2/en active Active
- 2011-09-05 DK DK11769799.5T patent/DK2753352T4/da active
- 2011-09-05 HR HRP20170193TT patent/HRP20170193T4/hr unknown
- 2011-09-05 ES ES11769799T patent/ES2631032T5/es active Active
- 2011-09-05 LT LTEP11769799.5T patent/LT2753352T/lt unknown
- 2011-09-05 EP EP21157982.6A patent/EP3895728A1/en active Pending
- 2011-09-05 PL PL11769799.5T patent/PL2753352T5/pl unknown
- 2011-09-05 WO PCT/EP2011/065304 patent/WO2012028741A1/en not_active Ceased
- 2011-09-05 ES ES16204515T patent/ES2867375T3/es active Active
- 2011-09-05 EP EP11769799.5A patent/EP2753352B2/en active Active
- 2011-09-05 CN CN201180073256.XA patent/CN103957931B/zh active Active
- 2011-09-05 SI SI201131113T patent/SI2753352T2/sl unknown
2014
- 2014-01-24 ZA ZA2014/00610A patent/ZA201400610B/en unknown
2017
- 2017-02-01 US US15/421,808 patent/US10357557B2/en active Active
- 2017-02-24 CY CY20171100260T patent/CY1118664T1/el unknown
2019
- 2019-03-07 US US16/295,031 patent/US10821166B2/en active Active
2020
- 2020-10-02 US US17/061,891 patent/US11357844B2/en active Active
2021
- 2021-08-19 US US17/406,765 patent/US11478540B2/en active Active
2022
- 2022-09-09 US US17/930,742 patent/US12324831B2/en active Active
2025
- 2025-05-08 US US19/202,001 patent/US20250360191A1/en active Pending

Also Published As

Publication number	Publication date
LT2753352T (lt)	2017-05-25
CA2873272C (en)	2020-10-27
CA2873272A1 (en)	2012-03-08
EP2753352B2 (en)	2022-08-10
US10357557B2 (en)	2019-07-23
US20210393761A1 (en)	2021-12-23
KR101907434B1 (ko)	2018-10-12
US20190290747A1 (en)	2019-09-26
AU2011298306B2 (en)	2017-10-19
ES2631032T3 (es)	2017-08-25
CY1118664T1 (el)	2017-07-12
EP2753352B1 (en)	2017-01-25
US11357844B2 (en)	2022-06-14
US20150056238A1 (en)	2015-02-26
HK1200357A1 (en)	2015-08-07
BR112014004896B1 (pt)	2023-02-14
BR112014004896A2 (pt)	2021-01-26
HUE033342T2 (en)	2017-11-28
US11478540B2 (en)	2022-10-25
US12324831B2 (en)	2025-06-10
DK2753352T4 (da)	2022-09-12
DK2753352T3 (da)	2017-03-06
PL2753352T5 (pl)	2022-10-17
US20170239340A1 (en)	2017-08-24
MX350126B (es)	2017-08-28
SI2753352T1 (sl)	2017-06-30
WO2012028741A1 (en)	2012-03-08
HRP20170193T1 (hr)	2017-06-02
RS55707B2 (sr)	2022-10-31
US20210121554A1 (en)	2021-04-29
DK2753352T5 (da)	2017-05-01
ZA201400610B (en)	2015-09-30
MX2014002595A (es)	2014-10-13
RS55707B1 (sr)	2017-07-31
EP2753352A1 (en)	2014-07-16
PL2753352T3 (pl)	2017-07-31
JP6121421B2 (ja)	2017-04-26
PT2753352T (pt)	2017-03-08
CN103957931A (zh)	2014-07-30
AU2011298306A1 (en)	2014-02-20
ES2631032T5 (es)	2022-10-26
JP2014525249A (ja)	2014-09-29
EP3895728A1 (en)	2021-10-20
ES2867375T3 (es)	2021-10-20
KR20140057315A (ko)	2014-05-12
CN103957931B (zh)	2017-10-24
US20230173052A1 (en)	2023-06-08
US9598472B2 (en)	2017-03-21
SMT201700124T1 (it)	2017-05-08
HRP20170193T4 (hr)	2022-09-02
EP3167899A1 (en)	2017-05-17
US20250360191A1 (en)	2025-11-27
EP3167899B1 (en)	2021-03-24
US10821166B2 (en)	2020-11-03

Publication	Publication Date	Title
ZA201400610B (en)	2015-09-30	Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
IL260045B (en)	2020-06-30	Polypeptide structures and their uses
WO2012024452A3 (en)	2012-06-07	Modified relaxin polypeptides and their uses
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
IL222961A0 (en)	2013-02-03	Novel dna-dinding proteins and uses thereof
IL222966A0 (en)	2013-02-03	Neuregulin isoforms, neuregulin polypeptides and uses thereof
IL236549A0 (en)	2015-02-26	Antibodies to a beta c-terminal or central epitope and uses thereof
EP2593595A4 (en)	2014-03-26	NOVEL PEPTIDES AND USES THEREOF
EP2892913A4 (en)	2017-01-18	Peptides and their uses
AU2011259204A1 (en)	2013-06-27	Antigen peptide and use thereof
AU2011259204A8 (en)	2013-07-04	Antigen peptide and use thereof
KR20180085063A (ko)	2018-07-25	신규 단백질 소재
EP3059243A4 (en)	2017-11-08	Yap protein inhibiting polypeptide and application thereof
IL225671A0 (en)	2013-06-27	Vaccines based on complement c5a protein peptides
TWI369211B (en)	2012-08-01	An isolated peptide and the preparation processes and applications thereof
EP2771689A4 (en)	2015-06-03	PEPTIDES USP2A AND ANTIBODIES
HK1192893A (en)	2014-09-05	Modified proteins and peptides
HK40017091A (en)	2020-09-18	Polypeptide constructs and uses thereof
AU2011904502A0 (en)	2011-11-17	Polypeptide constructs and uses thereof
HK1176365A (en)	2013-07-26	Modified melk peptides and vaccines containing the same
HK1183903A (en)	2014-01-10	C18orf54 peptides and vaccines including the same
HK1183902A (en)	2014-01-10	Wdhd1 peptides and vaccines including the same
IL231507B (en)	2021-03-25	Antibodies directed against marker peptides, methods and uses
GB201121226D0 (en)	2012-01-18	Modified proteins and peptides
GB201121233D0 (en)	2012-01-18	Modified proteins and peptides